within Pharmacolibrary.Drugs.ATC.C;

model C10AA07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.00022,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0715,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.037000000000000005,
    Tlag           = 24.0,            
    Vdp             = 0.107,
    k12             = 11.6,
    k21             = 11.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rosuvastatin is a synthetic lipid-lowering agent, classified as a statin (HMG-CoA reductase inhibitor), used for the treatment of high cholesterol and related conditions, and for the prevention of cardiovascular disease. It is widely approved and prescribed globally.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adult volunteers (both sexes), single oral dose.</p><h4>References</h4><ol><li><p>Jordy, AB, et al., &amp; Bækdal, TA (2021). Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <i>Clinical pharmacokinetics</i> 60(9) 1171–1185. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00976-x\">10.1007/s40262-020-00976-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33782832/\">https://pubmed.ncbi.nlm.nih.gov/33782832</a></p></li><li><p>Kanukula, R, et al., &amp; Kamel, B (2021). Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. <i>Clinical pharmacokinetics</i> 60(2) 165–175. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00978-9\">10.1007/s40262-020-00978-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33428168/\">https://pubmed.ncbi.nlm.nih.gov/33428168</a></p></li><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=\"https://doi.org/10.2165/00003088-200544050-00002\">10.2165/00003088-200544050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15871634/\">https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AA07;
